- Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF-?, in patients with advanced tumorsGuo, Ye; Liu, Baogang; Lv, Dongqing; Cheng, Ying; Zhou, Tong; Zhong, Yahua; Hu, Changlu; Chen, Gang; Wu, Xiaohua; Yin, Yongmei; Wu, Lihua; Chen, Zhendong; Luo, Hong; Zhou, Xiaohong; Qin, Yanru; Yang, Yuxing; Luo, Suxia; Ma, Yanjie; Li, Yalin; Hu, GuoqiangAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.被引 5
- A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/ TGF-bRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumorsXu, R-H.; Huiyan, L.; Zhao, H.; Wei, W.; Ma, D.; Yin, X.; Ni, Y.; Wang, Y.; Zhang, Y.; Zhou, J.; Pan, H.; Niu, Z.; Zhang, J.; Ren, H.; Kang, M.; Jia, W.; Gu, S.; Liu, P.; Zhang, Z.; Wang, S.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Camrelizumab plus famitinib as first-line treatment in advanced NSCLC patients with PD-L1 TPS ≥1%: A report from a multicenter, open-label, phase II basket trialRen, S.; Wang, X.; Han, B.; Pan, Y.; Zhao, J.; Cheng, Y.; Hu, S.; Liu, T.; Li, Y.; Cheng, Y.; Feng, J.; Yi, S.; Gu, S.; Gao, S.; Luo, Y.; Liu, Y.; Liu, C.; Duan, H.; Zhou, C.; Fan, J.
会议论文
A phase I study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-b, in patients with advanced nonsmall cell lung cancer (NSCLC)
6阅读
